Background. The Strategic Advisory Group of Experts on Immunization (SAGE) has recommended introduction of at least 1 dose of inactivated poliovirus vaccine (IPV) at ≥14 weeks of age through the routine immunization program in countries currently not using IPV.
paralytic polio cases worldwide, almost 40% are caused by type 2 [4] .
Considering that global interruption of WPV type 2 (WPV2) was achieved in 1999 [5] and that Sabin type 2 poliovirus has the potential to acquire neurovirulence, the global polio eradication initiative has proposed a phased removal of Sabin poliovirus types, starting with removal of type 2 Sabin poliovirus in routine and supplementary immunization after certain conditions are met [4] . In April 2013, the Strategic Advisory Group of Experts on Immunization (SAGE) of the World Health Organization supported the preeradication switch from tOPV to bivalent OPV (bOPV) and recommended introducing inactivated poliovirus vaccine (IPV) in routine immunization schedules in advance of the switch [5] . In November 2013, SAGE recommended that countries that introduce at least 1 dose of IPV in the routine immunization program should administer the first dose of IPV at ≥14 weeks of age [6] . In countries with a routine immunization schedule of 6, 10, and 14 weeks of age or 2, 3, and 4 months of age, IPV would then be added to the DTP dose 3 (DTP3) visit for children on schedule or administered at the first immunization visit at 14 weeks or later if children are off schedule [6] . For countries with a month 2, 4, and 6 schedule, IPV could be added to either the DTP2 visit or the DTP3 visit. SAGE also proposed that countries have the flexibility to consider alternative schedules, including administering IPV earlier than 14 weeks of age or administering >1 dose of IPV.
The principal objective of the preeradication introduction of IPV is to mitigate the risk associated with an increased susceptibility to type 2 polioviruses when bOPV is introduced. Therefore, it is essential to achieve the highest possible type 2 population immunity with IPV, which is a product of the per-dose immunogenicity of IPV and the coverage achieved by IPV at that vaccination visit in routine immunization. During infancy, the presence of maternally acquired antibodies diminishes the immunogenicity of IPV [1] . Because maternal antibody levels decline over time, vaccination schedules that delay the start of IPV immunization are associated with improved IPV immunogenicity [7, 8] . The improvement in IPV immunogenicity during infancy with increasing age of vaccination needs to be balanced against per-dose coverage levels of childhood vaccines, as these levels vary considerably from country to country. Furthermore, data on immunogenicity (seroconversion and priming) of IPV, by age, are limited. In a clinical trial conducted in Cuba, a single dose of IPV at 4 months of age achieved limited seroconversion (63%) although considerable priming (98%) against type 2 poliovirus [9] . This study is the only study that assessed seroconversion and priming with IPV at an age that corresponds to an age for vaccination according to the routine immunization schedule in some countries.
The objective of this analysis was to estimate the coverage of injectable routine childhood vaccination (DTP1/2/3 or pentavalent 1/2/3 and measles vaccine) as a proxy for likely IPV coverage. This analysis will aid in identifying the most appropriate target age and timing in the routine immunization schedule for introduction of IPV to achieve optimal vaccination coverage and the highest level of population immunity.
METHODS

Countries and Data Sources
The Demographic and Health Surveys (DHS) are nationally representative multistage cluster sample surveys [10] . We analyzed data from all countries in sub-Saharan Africa, South Asia, and Southeast Asia that have conducted a DHS since 2005 and for which unrestricted data sets were publicly available as of 5 November 2013 (sub-Saharan Africa, 31 
Outcome Variables
We determined the vaccination status of the youngest child aged 12-23 months in each household surveyed. The coverage of routinely administered injectable EPI vaccines (DTP1, DTP2, DTP3, measles vaccine, and their combinations) was estimated and used as a proxy measure for likely IPV coverage. In all selected countries except for Maldives, the DTP3 visit was the first recommended vaccine-associated visit at ≥14 weeks of age.
1 Dose of IPV SAGE has recommended introduction of 1 dose of IPV at ≥14 weeks of age. Therefore, DTP3 coverage was determined and compared with coverage with DTP1, DTP2, and measles vaccine, the vaccine-associated visits other than that for DTP3, at which an injectable vaccine is administered. The absolute percentage difference between DTP1 and DTP3 coverage was estimated, and the DTP1-DTP3 drop-out rate was calculated as follows: [DTP1 coverage − DTP3 coverage]/DTP1 coverage. The number of children in the birth cohort of each country who would not be able to receive IPV was estimated using the DHS DTP3 coverage estimate and the size of the 2011 birth cohort as estimated by the United Nations Children's Fund (UNICEF) [11] . By use of DTP1 and DTP3 coverage estimates, the number of additional children who would receive a single dose of IPV if DTP1 was used for administering IPV instead of DTP3 was estimated. 2 Doses of IPV SAGE has recommended that countries have the flexibility to choose their IPV schedules. Hence, coverage with 2 doses of injectable EPI vaccines given at 2 different target age visits through the routine immunization program was estimated as a proxy for likely coverage with 2 IPV doses. The vaccine-associated visit combinations were as follows: DTP1 and DTP3; DTP2 and DTP3; DTP1 and DTP2; DTP3 and measles vaccine; and DTP1 and measles vaccine. These visit combinations were selected because they are being actively considered by countries as visits during which 2 doses of IPV can be administered.
Data Analysis
Analysis was conducted using the survey feature of Stata, release 11.2 [12] . The analysis was weighted to account for the survey design and was based on households with at least 1 child aged 12-23 months at the time of the survey, with a sample size of 379 to 9994 children per country. Coverage estimates with 95% confidence intervals were determined by country and by vaccine visit. Medians and ranges of coverage estimates were calculated from country-level estimates for 1 and 2 doses of IPV, overall and separately for sub-Saharan Africa and for South and Southeast Asia. Overall, the median IPV coverage is estimated to be 13% (range, 0.7%-27%) higher if administered at the DTP1 visit, compared with the DTP3 visit. Using the 2011 birth cohort, this difference in coverage translates to an additional 12 million children receiving IPV (data not shown). The overall median DTP1-DTP3 drop-out rate is expected to be 14% (range, 0.7%-55%). Figure 1 illustrates the DTP1-DTP3 drop-out rate by DTP3 coverage. Countries with the lowest DTP3 coverages are also more likely to have the largest number of children who will not receive IPV if IPV is administered at the time DTP3 is administered ( Figure 1 ). These countries also have the highest DTP1-DTP3 drop-out rates. Figure 2A shows geographical clustering of children who did not receive DTP3. Figure 2B shows the potential impact of using the DTP1 visit for IPV administration on reducing the number of children who do not receive IPV.
RESULTS
Likely Coverage With 1 Dose of IPV
Likely Coverage With 2 Doses of IPV
Among the target age visits at which injectable EPI vaccines are administered, the overall median coverage with 2 doses of IPV is expected to be lowest if offered at the visits for DTP3 and measles vaccine ( 
DISCUSSION
This is the first systematic analysis to assess likely IPV coverage in the context of the proposed tOPV-bOPV switch as part of the endgame for polio eradication. In November 2013, SAGE recommended that in countries currently using OPV only in routine immunization, IPV should be added at the first immunization visit at ≥14 weeks of age whether DTP is recommended at 6, 10, and 14 weeks or 2, 3, and 4 months of age. SAGE also stated that countries have the flexibility to choose alternative schedules, including administering IPV earlier than 14 weeks of age. Our findings document the extent to which coverage with 1 dose of IPV at the DTP3 visit would be lower than at the DTP1 visit, particularly since the DTP1-DTP3 drop-out rate tends to be higher in countries with lower DTP3 coverage. If IPV is offered at the DTP3 visit, the countries with the lowest DTP3 coverage (and the highest DTP1-DTP3 drop-out rates) are countries that would likely have the largest cohorts of Figure 1 . Coverage with dose 3 of diphtheria-tetanus-pertussis vaccine (DTP3) and DTP1-DTP3 drop-out rate among children 12-23 months of age. The size of circles is proportional to number of children in a birth cohort who will not receive DTP3.
children who would not receive IPV. We noted geographical clustering of these countries in sub-Saharan Africa and in South and Southeast Asia. Therefore, if IPV is administered at the DTP3 visit instead of earlier and coverage levels are not substantially improved in these countries, there could be increased geographical clustering of children who have not received IPV and hence increased clustering of type 2 poliovirus susceptibility in countries of sub-Saharan Africa and of South and Southeast Asia.
In weighing the potential benefit of administering a single IPV dose with DTP1 or DTP3, data on the immunogenicity of IPV (ie, seroconversion and priming with IPV) by age is limited. A clinical trial in Cuba that assessed priming with IPV at 4 months of age is the only study that assessed priming with IPV at an age that corresponds to an existing age of routine vaccination in some countries [9] . Because population immunity is a function of both coverage and per-dose IPV immunogenicity, estimates of alternative schedules are limited by the uncertainty of per-dose immunogenicity by age and by the relative importance of priming and seroconversion. This highlights the need for clinical trials to obtain these data. In addition, efforts continue to improve the immunization programs in these countries, so the relative impact of options in the years when IPV is introduced may change.
Our findings, although not unexpected, should be interpreted with caution. As IPV has not been introduced in the analyzed Figure 2 . A, Number of children in a birth cohort who are likely to not receive dose 3 of diphtheria-tetanus-pertussis vaccine (DTP3), 2011.
countries, these coverage estimates may differ from IPV coverage in actual practice after IPV has been introduced. Administration of an additional injectable vaccine at the DTP1, DTP2, DTP3, or measles vaccine visit could positively or negatively affect acceptance of IPV (or even of DTP1, DTP2, DTP3, or measles vaccine). Vaccine receipt information in the DHS is a combination of observed card-recorded information and self-reports by the mother or caregiver. Therefore, vaccination information from DHS data could be affected by nonresponse, recall bias, and social-desirability bias. These theoretical estimates of IPV coverage are likely to be affected by the unique situation and the health centers in the country. The ability to deliver an additional injectable vaccine efficiently depends on many factors that cannot be accounted for in this analysis, including acceptability of the vaccine to the public and health providers, ability of the vaccine management system to cope with an additional vaccine in the schedule, adequate cold chain space for a new vaccine, and sufficient staffing and training of health providers.
In conclusion, country-specific IPV introduction decisions regarding the target age and the number of doses as part of the tOPV-bOPV switch needs to balance carefully the tradeoff between the expected age-related immune response to IPV and the likely age-related IPV coverage. This analysis is essentially the first step in assessing the impact on type 2 poliovirus susceptibility with IPV introduction and withdrawal of tOPV. Studies are needed to determine the immunogenicity (ie, priming and seroconversion) of IPV under different schedules of administration in the routine immunization program. Immunogenicity of IPV at different vaccination visits, combined with 95. 6-97.7 95.6-97.7 97.3-98.9 92.4-95.2 93.6-96.1 likely IPV coverage estimates at different vaccination visits, as determined in this analysis, should be used to estimate the type 2 poliovirus population immunity of the birth cohort, which would be the critical step in evaluating the different options for introducing IPV into the routine immunization schedule. As the primary purpose of introducing IPV is to prevent an increase in population susceptibility to type 2 poliovirus, choosing the vaccination schedule that offers the highest population immunity against type 2 poliovirus is important. At present, there is insufficient evidence to determine whether the SAGE-recommended IPV schedule for the polio endgame would maximize type 2 poliovirus population immunity. 
